Two Colorado studies find resistance mechanisms in ALK+ and ROS1+ cancers

“A University of Colorado Cancer Center study published today in the journal Clinical Cancer Research provides an in-depth look at how these ALK+ and ROS1+ cancers evolve to resist treatment. A second study demonstrates the ability to identify these changes in patient blood samples, perhaps easing the ability to monitor patients for these changes that provide early evidence that treatment is failing.”

Read the full article here

Public Release: 

Published by

lysa71

mom, wife, daughter, advocate, and stage IV lung cancer survivor.